Iris Hypoplasia with Glaucoma

Understanding the molecular and genetic underpinnings of iris hypoplasia with glaucoma is crucial for developing effective diagnostic and therapeutic strategies. Protheragen offers customized diagnostic and therapeutic solutions designed to target the specific genetic and molecular pathways involved in Iris Hypoplasia with Glaucoma.

Overview of Iris Hypoplasia with Glaucoma

Iris hypoplasia with glaucoma refers to a spectrum of developmental eye disorders characterized by underdevelopment of the iris and its associated structures, leading to increased intraocular pressure and potential optic nerve damage. This condition can manifest in various forms, with primary congenital glaucoma (PCG) being the most common type, affecting infants and young children. The disease is often genetic, with mutations in genes such as CYP1B1, LTBP2, and TEK implicated in its pathogenesis. Glaucoma in these cases is a significant cause of preventable blindness worldwide, emphasizing the need for effective diagnostics and therapies.

Fig.1 Major genes involved in iris development. (Daruich A., et al., 2023)

Diagnostics Development for Iris Hypoplasia with Glaucoma

High-throughput sequencing, such as Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS), is transforming our ability to diagnose this condition. These approaches allow for the comprehensive analysis of the genetic material, identifying mutations in key genes such as FOXC1 and PITX2. Such powerful tools not only help determine the genetic basis of the condition but also enable precision medicine strategies tailored to individual genetic profiles.

The identification of mutations in FOXC1 and PITX2 genes has been pivotal in understanding this condition. For instance, duplications or deletions on chromosome 6p25 involving FOXC1 have been directly linked to ocular developmental anomalies seen in patients with Iris Hypoplasia. Similarly, pathogenic variants in PITX2 are known to disrupt ocular angioarchitecture, emphasizing the crucial role of these genes in diagnosis and therapeutic decision-making.

Therapeutics Development for Iris Hypoplasia with Glaucoma

Our Services

With extensive experience, Protheragen is committed to providing professional diagnostics and therapy development services for iris hypoplasia with glaucoma. Leveraging our expertise in molecular biology, we are developing targeted genetic therapies to correct or compensate for the mutations causing iris hypoplasia with glaucoma. These therapies aim to restore normal gene function, potentially halting or reversing the disease process.

Target Identification and Validation Services for IHG

Protheragen supports the discovery and functional validation of disease‑relevant targets by linking IHG genetic mutations to molecular and cellular phenotypes. Services include:

• Bioinformatic and genomic analysis of PAX6, FOXC1, PITX2, and other ASD‑associated loci to identify druggable signaling nodes
• In vitro validation using patient‑derived and gene‑edited cellular models of iris stromal hypoplasia
• Quantitative assays for target expression, localization, and functional activity in anterior segment cell lineages
• Mechanistic studies to connect target modulation to improved iris development, trabecular meshwork function, and aqueous outflow

These services clarify which molecular pathways drive both iris maldevelopment and glaucoma, enabling rational selection of high‑value therapeutic targets.

In Vitro Model Development and Therapeutic Screening

Protheragen develops and deploys standardized in vitro systems for high‑throughput and mechanistic screening of IHG drug candidates:

• Primary and immortalized cell models of human iris stromal fibroblasts, trabecular meshwork cells, and Schlemm's canal endothelial cells carrying IHG‑associated mutations
• 3D anterior segment organoids derived from human induced pluripotent stem cells (hiPSCs) that recapitulate iris hypoplasia and angle dysgenesis
• Phenotypic screening assays for iris stromal maturation, extracellular matrix remodeling, cell survival, and barrier function
• Medium‑ to high‑throughput screening for IOP‑lowering, neuroprotective, and tissue‑remodeling compounds

In vitro data enable rapid rank‑ordering of candidates, dose–response characterization, and early elimination of toxic or ineffective molecules before in vivo studies.

In Vivo Preclinical Efficacy and Safety Assessment

Protheragen provides customized in vivo studies using genetically engineered models replicating key IHG features:

• Longitudinal IOP measurement and gonioscopic evaluation of iridocorneal angle structure
• In vivo ophthalmic imaging including OCT for iris thickness, angle anatomy, and optic nerve head morphology
• Histological and immunohistochemical assessment of iris stromal density, trabecular meshwork maturation, and RGC survival
• Pharmacodynamic (PD) evaluation of candidate effects on aqueous humor dynamics and tissue regeneration
• GLP‑compliant safety pharmacology, toxicokinetics, and local ocular tolerability testing

Studies are designed to quantify therapeutic benefit for both the structural iris defect and glaucomatous progression, supporting robust translation to clinical development.

Ocular Drug Delivery and Formulation Development for IHG

Effective anterior segment penetration is critical for IHG therapeutics. Protheragen offers specialized formulation services:

• Formulation design for topical, intracameral, and subconjunctival delivery to target iris and anterior chamber tissues
• Development of sustained‑release systems including microspheres, liposomes, and in situ gels for prolonged intraocular exposure
• Ex vivo ocular tissue distribution and penetration studies using human and animal anterior segments
• Stability, sterility, and excipient compatibility testing for ophthalmic dosage forms

Optimized delivery improves target engagement and reduces systemic exposure, supporting a favorable therapeutic index for chronic IHG treatment.

Biomarker Development and Quantitative Pharmacodynamic Assays

Protheragen establishes non‑invasive and tissue‑based pharmacodynamic biomarkers to monitor therapeutic response:

• Molecular biomarkers including gene expression and protein levels in anterior segment tissues
• Imaging biomarkers derived from OCT, gonioscopy, and tonometry
• Functional biomarkers including aqueous outflow facility and pupillary responses
• Assay validation and standardization for consistent longitudinal monitoring

Biomarkers enable objective, quantitative assessment of therapeutic efficacy in preclinical studies and support clinical trial endpoint design.

Diagnostics Development

• Karyotype Analysis Service
• Omics Analysis Service
• Biomarker Development Service
• Artificial Intelligence Service
• Customized Diagnostics Development

Therapeutic Development

• Small Molecule Drug
• Cell Therapy
• Gene Therapy
• Therapeutic Antibody
• Therapeutic Peptide
• Therapeutic Protein
• Customized Therapy Development

Disease Models

• CYP1B1 Mutation Animal Models
• LTBP2 Mutation Animal Models
• TEK Mutation Animal Models
• Customized Disease Model Development

Protheragen's preclinical research services are dedicated to the discovery and validation of new therapeutic strategies for iris hypoplasia with glaucoma. Our state-of-the-art facilities and experienced team conduct rigorous testing to ensure the efficacy and safety of new therapeutics. If you are interested in our services, please feel free to contact us.

References

• Daruich, Alejandra, et al. "Congenital aniridia beyond black eyes: from phenotype and novel genetic mechanisms to innovative therapeutic approaches." Progress in retinal and eye research 95 (2023): 101133.
• Iureva, Tatiana, Andrey Shchuko, and Yulia Pyatova. "Diagnostics and Prediction of Glaucoma in Patients with Familial Congenital Iris Hypoplasia." Open Journal of Ophthalmology 5.3 (2015): 115-123.